ALSO READAurobindo bets on Eastern Europe with larger product base, acquisition Aurobindo Pharma's Q1 a miss, but much better than peers Aurobindo Pharma gets USFDA nod for heartburn drug Aurobindo to widen portfolio in US, enter new European markets in 3-4 years Aurobindo Pharma surges 8% on USFDA nod for Sevelamer Carbonate tablets
Apart from acquisitions, the company is also keen to expand its product portfolio in the US and Western European markets with high-value drugs.
The high-value products that are in the pipeline include oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars, the company said.
"Our acquisition strategy will be largely around two platforms. One is to penetrate markets deeper and the other to secure newer technologies and platforms. We always maintain that anything that can come across in Eastern Europe will be prioritised," Aurobindo Pharma's managing director N Govindarajan said in an earnings presentation.
But he was quick to add that there is no pressure on him to do an acquisition to fill any gap as "there is enough opportunities to grow organically".
Earlier this year, the company announced acquisition of Portugal's Generis Farmaceutica SA from Magnum Capital Partners for a consideration of Euro 135 million (around Rs 969 crore).
The acquisition of Generis, by leveraging its strong portfolio and unrivalled brand recognition is expected to allow the company to establish itself as the top generics player in the Portuguese market.
On product expansion into existing markets, he said, "The portfolio mix is complemented with the introduction of high-value products and the future pipeline that includes oncology, hormones, depot injections, peptides, inhalers, patches and films, vaccines and biosimilars."
For FY18, it plans to spend about $130 million towards capex in vaccines and biosimilar.
During the second quarter, its revenue rose 17 per cent to Rs 4,436 crore driven by strong growth across key markets, boosting its bottom line by 29 per cent to Rs 781 crore.
Formulation business contributed 83 per cent of total sales and with Rs 3,663 crore, registering a 22 per cent growth. API business accounted for the balance of Rs 772 crore in Q2.
In the formulations business, total sales from the US markets stood at Rs 2,099 crore, an increase of 21 per cent year-on-year. The growth was primarily driven by new products and improved volumes of existing products.
"We have launched eight products, including two injectables in the September quarter. Aurobindo USA has witnessed a growth of 37 per cent in the quarter driven by new product launches and higher volume," Govindarajan said.
The company has filed a total of 90 injectable ANDAs as of end September, of which 51 have already been approved-- two tentative approvals and the rest are under review with USFDA.
He expects injectable business, which has already ramped up well, to grow by at least 40 per cent this fiscal. But oral division disappointed with a price erosion of 9-11 per cent.
"Even though there is pressure, we still believe we would be able to grow our US business because there are lot of opportunities for growing the volume as well to launch some new products," Govindarajan said.